Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40+
SponsorOvationLab

About this trial

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult females or males age ≥ 40 years

Ability to read and speak English

Disqualifiers

Current use of a dietary supplement containing fulvic or humic acid

Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella

Known allergies to any ingredients in the product

Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks

Trial design

Design model

Single group

Treatments tested in this trial

  • Humic and Fulvic Acid Dietary Supplement

    Dietary supplement

    BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Humic and Fulvic Acid Dietary SupplementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

TruDiagnostic - Epigenetic Testing

TruAge Test

Time frame
Change in TruAge from baseline to 12 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.